Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 31, 2022

SELL
$3.23 - $4.6 $182,982 - $260,594
-56,651 Closed
0 $0
Q3 2021

Nov 03, 2021

SELL
$3.47 - $4.42 $27,784 - $35,390
-8,007 Reduced 12.38%
56,651 $207,000
Q2 2021

Jul 30, 2021

BUY
$3.94 - $4.92 $99,366 - $124,082
25,220 Added 63.95%
64,658 $282,000
Q1 2021

Apr 29, 2021

SELL
$4.23 - $6.55 $34,216 - $52,982
-8,089 Reduced 17.02%
39,438 $179,000
Q4 2020

Jan 28, 2021

SELL
$5.73 - $9.03 $20,324 - $32,029
-3,547 Reduced 6.94%
47,527 $273,000
Q3 2020

Oct 29, 2020

BUY
$3.32 - $7.24 $169,565 - $369,775
51,074 New
51,074 $370,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Dupont Capital Management Corp Portfolio

Follow Dupont Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Dupont Capital Management Corp with notifications on news.